These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 30864840)

  • 61. Clinical association between the metabolite of healthy gut microbiota, 3-indolepropionic acid and chronic kidney disease.
    Sun CY; Lin CJ; Pan HC; Lee CC; Lu SC; Hsieh YT; Huang SY; Huang HY
    Clin Nutr; 2019 Dec; 38(6):2945-2948. PubMed ID: 30612852
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of Synbiotic Therapy on Gut-Derived Uremic Toxins and the Intestinal Microbiome in Patients with CKD.
    Vaziri ND
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):199-201. PubMed ID: 26772192
    [No Abstract]   [Full Text] [Related]  

  • 63. Intestinal Barrier Function in Chronic Kidney Disease.
    Meijers B; Farré R; Dejongh S; Vicario M; Evenepoel P
    Toxins (Basel); 2018 Jul; 10(7):. PubMed ID: 30029474
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The clinical impact of gut microbiota in chronic kidney disease.
    Kim SM; Song IH
    Korean J Intern Med; 2020 Nov; 35(6):1305-1316. PubMed ID: 32872729
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Manipulating the gut microbiome to decrease uremic toxins.
    Yacoub R; Wyatt CM
    Kidney Int; 2017 Mar; 91(3):521-523. PubMed ID: 28202164
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Novel intestinal dialysis interventions and microbiome modulation to control uremia.
    Sumida K; Lau WL; Kalantar-Zadeh K; Kovesdy CP
    Curr Opin Nephrol Hypertens; 2022 Jan; 31(1):82-91. PubMed ID: 34846313
    [TBL] [Abstract][Full Text] [Related]  

  • 67. p-Cresyl Sulfate.
    Gryp T; Vanholder R; Vaneechoutte M; Glorieux G
    Toxins (Basel); 2017 Jan; 9(2):. PubMed ID: 28146081
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Gut microbiome and kidney disease: a bidirectional relationship.
    Al Khodor S; Shatat IF
    Pediatr Nephrol; 2017 Jun; 32(6):921-931. PubMed ID: 27129691
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Alterations of intestinal barrier and microbiota in chronic kidney disease.
    Sabatino A; Regolisti G; Brusasco I; Cabassi A; Morabito S; Fiaccadori E
    Nephrol Dial Transplant; 2015 Jun; 30(6):924-33. PubMed ID: 25190600
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Understanding and Therapeutic Strategies of Chinese Medicine on Gut-Derived Uremic Toxins in Chronic Kidney Disease.
    Guo C; Rao XR
    Chin J Integr Med; 2018 Jun; 24(6):403-405. PubMed ID: 29752692
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease.
    Li DY; Tang WHW
    Semin Nephrol; 2018 Mar; 38(2):193-205. PubMed ID: 29602401
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Intestinal Microbiota in Type 2 Diabetes and Chronic Kidney Disease.
    Sabatino A; Regolisti G; Cosola C; Gesualdo L; Fiaccadori E
    Curr Diab Rep; 2017 Mar; 17(3):16. PubMed ID: 28271466
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease.
    Raj D; Tomar B; Lahiri A; Mulay SR
    Pharmacol Res; 2020 Feb; 152():104617. PubMed ID: 31881272
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].
    Han WB; Liu YL; Wan YG; Sun W; Tu Y; Yang JJ; Wu W; He WM; Yao J
    Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2425-2432. PubMed ID: 28840678
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial.
    Poesen R; Evenepoel P; de Loor H; Delcour JA; Courtin CM; Kuypers D; Augustijns P; Verbeke K; Meijers B
    PLoS One; 2016; 11(4):e0153893. PubMed ID: 27100399
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease.
    Yang T; Richards EM; Pepine CJ; Raizada MK
    Nat Rev Nephrol; 2018 Jul; 14(7):442-456. PubMed ID: 29760448
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Could physical exercise help modulate the gut microbiota in chronic kidney disease?
    Esgalhado M; Borges NA; Mafra D
    Future Microbiol; 2016 May; 11():699-707. PubMed ID: 27159232
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.
    Fernandez-Prado R; Esteras R; Perez-Gomez MV; Gracia-Iguacel C; Gonzalez-Parra E; Sanz AB; Ortiz A; Sanchez-Niño MD
    Nutrients; 2017 May; 9(5):. PubMed ID: 28498348
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Colonic dialysis can influence gut flora to protect renal function in patients with pre-dialysis chronic kidney disease.
    Li Y; Dai M; Yan J; Liu F; Wang X; Lin L; Huang M; Li C; Wen R; Qin J; Xu H
    Sci Rep; 2021 Jun; 11(1):12773. PubMed ID: 34140540
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Microbiome in Chronic Kidney Disease (CKD): An Omics Perspective.
    Lohia S; Vlahou A; Zoidakis J
    Toxins (Basel); 2022 Feb; 14(3):. PubMed ID: 35324673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.